Advertisement

T Cell Mulfunction in the Tumor Environment

  • Eitan YefenofEmail author
Chapter

Abstract

The cancer microenvironment may be envisaged as a battlefield of a fight between the host’s immune system and the tumor. An army of T lymphocytes, which are trained to combat bacterial and viral infections, is mobilized to attack the tumor, but most of the times succumbs to its powers and lose the war. A major reason for this failure is the unique composition of the cancer microenvironment, which is shaped by the tumor in favor of its progression. The immunosuppressive environment of the tumor makes it a hard place for T cells to exert their otherwise powerful effector functions. The study of the cancer microenvironment yields important insights into the nature of the tumor protective shields surrounding the tumor. Recent studies bring new prospects for intervention therapies based on recruitment and activation of T cells at the cancer microenvironment.

Keywords

T cells Cancer Tumor microenvironment Immunosuppression Cytotoxic lymphocytes Regulatory T cells 

Notes

Acknowledgments

The author would like to acknowledge support from Concern Foundation, Los Angeles, the German-Israel Foundation (GIF) and the Jewish Founders Network.

References

  1. Ahmadzadeh M, Johnson LA, Heemskerk B et al (2009) Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114:1537–1544PubMedCrossRefGoogle Scholar
  2. Andersen RS, Thrue CA, Junker N et al (2012) Dissection of T-cell antigen specificity in human melanoma. Cancer Res 72:1642–1650Google Scholar
  3. Badoual C, Hans S, Fridman WH, Brasnu D, Erdman S, Tartour E (2009) Revisiting the prognostic value of regulatory T cells in patients with cancer. J Clin Oncol 27:e5–6; author reply e7Google Scholar
  4. Baniyash M (2004) TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol 4:675–687PubMedCrossRefGoogle Scholar
  5. Beal AM, Anikeeva N, Varma R et al (2008) Protein kinase C theta regulates stability of the peripheral adhesion ring junction and contributes to the sensitivity of target cell lysis by CTL. J Immunol 181:4815–4824PubMedGoogle Scholar
  6. Benatar T, Cao MY, Lee Y et al (2008) Virulizin induces production of IL-17E to enhance antitumor activity by recruitment of eosinophils into tumors. Cancer Immunol Immunother 57:1757–1769PubMedCrossRefGoogle Scholar
  7. Benatar T, Cao MY, Lee Y et al (2010) IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo. Cancer Immunol Immunother 59:805–817Google Scholar
  8. Benchetrit F, Ciree A, Vives V et al (2002) Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 99:2114–2121PubMedCrossRefGoogle Scholar
  9. Biswas SK, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11:889–896Google Scholar
  10. Blackburn SD, Shin H, Haining WN et al (2009) Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 10:29–37PubMedCrossRefGoogle Scholar
  11. Blesson S, Thiery J, Gaudin C et al (2002) Analysis of the mechanisms of human cytotoxic T lymphocyte response inhibition by NO. Int Immunol 14:1169–1178PubMedCrossRefGoogle Scholar
  12. Boissonnas A, Scholer-Dahirel A, Simon-Blancal V (2010) Foxp3+ T cells induce perforin-dependent dendritic cell death in tumor-draining lymph nodes. Immunity 32:266–278Google Scholar
  13. Bollard CM, Huls MH, Buza E et al (2006) Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma. Clin Lymphoma Myeloma 6:342–347PubMedCrossRefGoogle Scholar
  14. Bronstein-Sitton N, Cohen-Daniel L, Vaknin I et al (2003) Sustained exposure to bacterial antigen induces interferon-gamma-dependent T cell receptor zeta down-regulation and impaired T cell function. Nat Immunol 4:957–964PubMedCrossRefGoogle Scholar
  15. Bronte V, Zanovello P (2005) Regulation of immune responses by l-arginine metabolism. Nat Rev Immunol 5:641–654PubMedCrossRefGoogle Scholar
  16. Bunt SK, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S (2006) Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol 176:284–290PubMedGoogle Scholar
  17. Burnet M (1957) Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br Med J 1:841–847PubMedCrossRefGoogle Scholar
  18. Burnet FM (1971) Immunological surveillance in neoplasia. Transplant Rev 7:3–25PubMedGoogle Scholar
  19. Carreno BM, Collins M (2002) The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Ann Rev Immunol 20:29–53CrossRefGoogle Scholar
  20. Cederbaum SD, Yu H, Grody WW, Kern RM, Yoo P, Iyer RK (2004) Arginases I and II: do their functions overlap? Mol Genet Metab 81(Suppl 1):S38–S44PubMedCrossRefGoogle Scholar
  21. Cerottini JC, Nordin AA, Brunner KT (1970) Specific in vitro cytotoxicity of thymus-derived lymphocytes sensitized to alloantigens. Nature 228:1308–1309PubMedCrossRefGoogle Scholar
  22. Charles KA, Kulbe H, Soper R et al (2009) The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 119:3011–3023PubMedCrossRefGoogle Scholar
  23. Chen CA, Ho CM, Chang MC et al (2010) Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis. Mol Ther 18:1233–1243Google Scholar
  24. Chiou SH, Sheu BC, Chang WC, Huang SC, Hong-Nerng H (2005) Current concepts of tumor-infiltrating lymphocytes in human malignancies. J Reprod Immunol 67:35–50PubMedCrossRefGoogle Scholar
  25. Chizzolini C, Chicheportiche R, Alvarez M et al (2008) Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. Blood 112:3696–3703PubMedCrossRefGoogle Scholar
  26. Cho Y, Miyamoto M, Kato K et al (2003) CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res 63:1555–1559PubMedGoogle Scholar
  27. Curiel TJ, Wei S, Dong H et al (2003) Blockade of B7–H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 9:562–567PubMedCrossRefGoogle Scholar
  28. Currie AJ, Prosser A, McDonnell A et al (2009) Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation. J Immunol 183:7898–7908PubMedCrossRefGoogle Scholar
  29. Deaglio S, Dwyer KM, Gao W et al (2007) Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204:1257–1265PubMedCrossRefGoogle Scholar
  30. Debatin KM, Krammer PH (2004) Death receptors in chemotherapy and cancer. Oncogene 23:2950–2966PubMedCrossRefGoogle Scholar
  31. Ezernitchi AV, Vaknin I, Cohen-Daniel L et al (2006) TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J Immunol 177:4763–4772PubMedGoogle Scholar
  32. Facciabene A, Peng X, Hagemann IS et al (2011) Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 475:226–230Google Scholar
  33. Fallarino F, Grohmann U, You S et al (2006) The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 176:6752–6761PubMedGoogle Scholar
  34. Fischer K, Hoffmann P, Voelkl S et al (2007) Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109:3812–3819PubMedCrossRefGoogle Scholar
  35. Fontenot JD, Dooley JL, Farr AG, Rudensky AY (2005) Developmental regulation of Foxp3 expression during ontogeny. J Exp Med 202:901–906PubMedCrossRefGoogle Scholar
  36. Fourcade J, Sun Z, Benallaoua M et al (2010) Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 207:2175–2186Google Scholar
  37. Freedman LR, Cerottini JC, Brunner KT (1972) In vivo studies of the role of cytotoxic T cells in tumor allograft immunity. J Immunol 109:1371–1378PubMedGoogle Scholar
  38. Fridman WH, Galon J, Pages F, Tartour E, Sautes-Fridman C, Kroemer G (2011) Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 71:5601–5605Google Scholar
  39. Fridman WH, Pages F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12:298–306Google Scholar
  40. Ghiringhelli F, Puig PE, Roux S et al (2005) Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+ CD25+ regulatory T cell proliferation. J Exp Med 202:919–929PubMedCrossRefGoogle Scholar
  41. Gobert M, Treilleux I, Bendriss-Vermare N et al (2009) Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 69:2000–2009PubMedCrossRefGoogle Scholar
  42. Greenwald RJ, Freeman GJ, Sharpe AH (2005) The B7 family revisited. Ann Rev Immunol 23:515–548CrossRefGoogle Scholar
  43. Harrington LE, Hatton RD, Mangan PR et al (2005) Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6:1123–1132PubMedCrossRefGoogle Scholar
  44. Hirahara N, Nio Y, Sasaki S et al (2001) Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice. Oncology 61:79–89PubMedCrossRefGoogle Scholar
  45. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057–1061PubMedCrossRefGoogle Scholar
  46. Huang S, Apasov S, Koshiba M, Sitkovsky M (1997) Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood 90:1600–1610PubMedGoogle Scholar
  47. Huang B, Pan PY, Li Q et al (2006) Gr-1+ CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66:1123–1131PubMedCrossRefGoogle Scholar
  48. Hurwitz AA, Watkins SK (2012) Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells. Cancer Immunol Immunother 61:289–293Google Scholar
  49. Igney FH, Krammer PH (2005) Tumor counterattack: fact or fiction? Cancer Immunol Immunother 54:1127–1136PubMedCrossRefGoogle Scholar
  50. Jones E, Dahm-Vicker M, Golgher D, Gallimore A (2003) CD25+ regulatory T cells and tumor immunity. Immunol Lett 85:141–143PubMedCrossRefGoogle Scholar
  51. Kanterman J, Sade-Feldman M, Baniyash M (2012) New insights into chronic inflammation-induced immunosuppression. Semin Cancer Biol 22:307–318Google Scholar
  52. Klein G, Klein E (1977) Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution. Proc Natl Acad Sci U S A 74:2121–2125PubMedCrossRefGoogle Scholar
  53. Kolls JK, Linden A (2004) Interleukin-17 family members and inflammation. Immunity 21:467–476PubMedCrossRefGoogle Scholar
  54. Kryczek I, Wei S, Zou L et al (2007) Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 178:6730–6733PubMedGoogle Scholar
  55. Kwek SS, Cha E, Fong L (2012) Unmasking the immune recognition of prostate cancer with CTLA4 blockade. Nat Rev Cancer 12:289–297Google Scholar
  56. Lai P, Rabinowich H, Crowley-Nowick PA, Bell MC, Mantovani G, Whiteside TL (1996) Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res 2:161–173PubMedGoogle Scholar
  57. Lathrop SK, Santacruz NA, Pham D, Luo J, Hsieh CS (2008) Antigen-specific peripheral shaping of the natural regulatory T cell population. J Exp Med 205:3105–3117PubMedCrossRefGoogle Scholar
  58. Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734–1736PubMedCrossRefGoogle Scholar
  59. Lee GK, Park HJ, Macleod M, Chandler P, Munn DH, Mellor AL (2002) Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology 107:452–460PubMedCrossRefGoogle Scholar
  60. Lehe C, Ghebeh H, Al-Sulaiman A et al (2008) The Wilms’ tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy. Cancer Res 68:6350–6359PubMedCrossRefGoogle Scholar
  61. Leveque L, Deknuydt F, Bioley G et al (2009) Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells. J Immunother 32:101–108PubMedCrossRefGoogle Scholar
  62. Liddy N, Bossi G, Adams KJ et al (2012) Monoclonal TCR-redirected tumor cell killing. Nat Med 18:980–7Google Scholar
  63. Mangan PR, Harrington LE, O’Quinn DB et al (2006) Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441:231–234PubMedCrossRefGoogle Scholar
  64. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23:549–555PubMedCrossRefGoogle Scholar
  65. Mantovani A, Allavena P, Sica A (2004) Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer 40:1660–1667PubMedCrossRefGoogle Scholar
  66. Martin-Orozco N, Muranski P, Chung Y et al (2009) T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31:787–798PubMedCrossRefGoogle Scholar
  67. McAllister F, Henry A, Kreindler JL et al (2005) Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J Immunol 175:404–412PubMedGoogle Scholar
  68. Middleton GW, Annels NE, Pandha HS (2012) Are we ready to start studies of Th17 cell manipulation as a therapy for cancer? Cancer Immunol Immunother 61:1–7Google Scholar
  69. Miller JF (1961) Immunological function of the thymus. Lancet 2:748–749PubMedCrossRefGoogle Scholar
  70. Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J, Wang RF (2008) Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci U S A 105:15505–15510PubMedCrossRefGoogle Scholar
  71. Movahedi K, Laoui D, Gysemans C et al (2010) Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 70:5728–5739Google Scholar
  72. Nagaraj S, Gupta K, Pisarev V et al (2007) Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 13:828–835PubMedCrossRefGoogle Scholar
  73. Nakagomi H, Petersson M, Magnusson I et al (1993) Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 53:5610–5612PubMedGoogle Scholar
  74. Nardin A, Abastado JP (2008) Macrophages and cancer. Front Biosci 13:3494–3505PubMedCrossRefGoogle Scholar
  75. Numasaki M, Fukushi J, Ono M et al (2003) Interleukin-17 promotes angiogenesis and tumor growth. Blood 101:2620–2627PubMedCrossRefGoogle Scholar
  76. Numasaki M, Watanabe M, Suzuki T et al (2005) IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 175:6177–6189PubMedGoogle Scholar
  77. Ochsenbein AF, Klenerman P, Karrer U et al (1999) Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci U S A 96:2233–2238PubMedCrossRefGoogle Scholar
  78. Ohta A, Gorelik E, Prasad SJ et al (2006) A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A 103:13132–13137PubMedCrossRefGoogle Scholar
  79. Ong SM, Tan YC, Beretta O et al (2012) Macrophages in human colorectal cancer are pro-inflammatory and prime T cells towards an anti-tumour type-1 inflammatory response. Eur J Immunol 42:89–100Google Scholar
  80. Ostrand-Rosenberg S (2009a) Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 59:1593–1600Google Scholar
  81. Ostrand-Rosenberg S, Sinha P (2009b) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182:4499–4506PubMedCrossRefGoogle Scholar
  82. Park H, Li Z, Yang XO et al (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6:1133–1141PubMedCrossRefGoogle Scholar
  83. Peggs KS, Quezada SA, Korman AJ, Allison JP (2006) Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 18:206–213PubMedCrossRefGoogle Scholar
  84. Rech AJ, Vonderheide RH (2009) Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 1174:99–106PubMedCrossRefGoogle Scholar
  85. Reichert TE, Rabinowich H, Johnson JT, Whiteside TL (1998) Mechanisms responsible for signaling and functional defects. J Immunother 21:295–306PubMedCrossRefGoogle Scholar
  86. Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL (2002) Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 8:3137–3145PubMedGoogle Scholar
  87. Rivoltini L, Carrabba M, Huber V et al (2002) Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 188:97–113PubMedCrossRefGoogle Scholar
  88. Rodriguez PC, Ochoa AC (2008) Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 222:180–191PubMedCrossRefGoogle Scholar
  89. Rodriguez PC, Zea AH, Culotta KS, Zabaleta J, Ochoa JB, Ochoa AC (2002) Regulation of T cell receptor CD3zeta chain expression by l-arginine. J Biol Chem 277:21123–21129PubMedCrossRefGoogle Scholar
  90. Rodriguez PC, Quiceno DG, Ochoa AC (2007) l-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 109:1568–1573PubMedCrossRefGoogle Scholar
  91. Rosenberg SA (2012) Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med 4:127ps8Google Scholar
  92. Serafini P, Mgebroff S, Noonan K, Borrello I (2008) Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 68:5439–5449PubMedCrossRefGoogle Scholar
  93. Shafer-Weaver KA, Watkins SK, Anderson MJ et al (2009) Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells. Cancer Res 69:6256–6264PubMedCrossRefGoogle Scholar
  94. Shimizu J, Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+ CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211–5218PubMedGoogle Scholar
  95. Singer K, Gottfried E, Kreutz M, Mackensen A (2011) Suppression of T-cell responses by tumor metabolites. Cancer Immunol Immunother 60:425–431Google Scholar
  96. Sinha P, Clements VK, Ostrand-Rosenberg S (2005) Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res 65:11743–11751PubMedCrossRefGoogle Scholar
  97. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G (2008) Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol 181:4666–4675PubMedGoogle Scholar
  98. Smyth MJ, Godfrey DI, Trapani JA (2001) A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2:293–299PubMedCrossRefGoogle Scholar
  99. Song X, Krelin Y, Dvorkin T et al (2005) CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J Immunol 175:8200–8208PubMedGoogle Scholar
  100. Sullivan R, Purushotham AD (2011) Avoiding the zero sum game in global cancer policy: beyond 2011 UN high level summit. Eur J Cancer 47:2375–80Google Scholar
  101. Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC (2006) A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 203:1685–1691PubMedCrossRefGoogle Scholar
  102. Takahashi H, Numasaki M, Lotze MT, Sasaki H (2005) Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol Lett 98:189–193PubMedCrossRefGoogle Scholar
  103. Taylor DD, Bender DP, Gercel-Taylor C, Stanson J, Whiteside TL (2001) Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients. Br J Cancer 84:1624–1629PubMedCrossRefGoogle Scholar
  104. Thomas L (1959) In: Lawrence HS (ed) Cellular and humoral aspects of the hypersensitive state. Hober-Harper, New York, p 529Google Scholar
  105. Uyttenhove C, Pilotte L, Theate I et al (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9:1269–1274PubMedCrossRefGoogle Scholar
  106. Valitutti S, Muller S, Dessing M, Lanzavecchia A (1996) Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J Exp Med 183:1917–1921PubMedCrossRefGoogle Scholar
  107. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B (2006) TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24:179–189PubMedCrossRefGoogle Scholar
  108. Vignali DA, Collison LW, Workman CJ (2008) How regulatory T cells work. Nat Rev Immunol 8:523–532PubMedCrossRefGoogle Scholar
  109. Walker MR, Kasprowicz DJ, Gersuk VH et al (2003) Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+ CD25− T cells. J Clin Invest 112:1437–1443PubMedGoogle Scholar
  110. Watkins SK, Hurwitz AA (2012) FOXO3: a master switch for regulating tolerance and immunity in dendritic cells. Oncoimmunology 1:252–254Google Scholar
  111. Watkins SK, Zhu Z, Riboldi E et al (2011) FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest 121:1361–1372Google Scholar
  112. Wing K, Onishi Y, Prieto-Martin P et al (2008) CTLA-4 control over Foxp3+ regulatory T cell function. Science 322:271–275PubMedCrossRefGoogle Scholar
  113. Wu S, Rhee KJ, Albesiano E et al (2009) A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 15:1016–1022PubMedCrossRefGoogle Scholar
  114. Ye J, Su X, Hsueh EC et al Human tumor-infiltrating Th17 cells have the capacity to differentiate into IFN-gamma+ and FOXP3+ T cells with potent suppressive function. Eur J Immunol 41:936–51Google Scholar
  115. Young MR, Newby M, Wepsic HT (1987) Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. Cancer Res 47:100–105PubMedGoogle Scholar
  116. Zajac AJ, Blattman JN, Murali-Krishna K et al (1998) Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 188:2205–2213PubMedCrossRefGoogle Scholar
  117. Zhang L, Conejo-Garcia JR, Katsaros D et al (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203–213PubMedCrossRefGoogle Scholar
  118. Zhang B, Rong G, Wei H et al (2008) The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun 374:533–537PubMedCrossRefGoogle Scholar
  119. Zhou G, Drake CG, Levitsky HI (2006) Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 107:628–636PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  1. 1.The Lautenberg Center for Immunology and Cancer ResearchThe Hebrew University-Hadassah Medical SchoolJerusalemIsrael

Personalised recommendations